Investigating breast cancer treatments for Black and African American populations
Pilot Research Project: Evaluating Black and African American Breast Cancer Populations for Therapeutic Targeting of Aberrant p53, MDM2, MDMX, and PARP signaling
This study is looking at what makes aggressive triple negative breast cancer more common in Black and African American people, with the goal of finding new ways to treat it better and helping patients understand their options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10931749 on NIH RePORTER |
What this research studies
This research focuses on understanding the unique biological factors that contribute to aggressive triple negative breast cancer (TNBC) in Black and African American individuals. By analyzing existing breast cancer samples from this population, the project aims to identify specific biomarkers that could lead to more effective targeted therapies. The research team, consisting of scientists from Hunter College and Temple University Fox Chase Cancer Center, will also work to educate the community about these biomarkers, empowering patients to engage in their treatment decisions. Additionally, the project includes mentoring opportunities for underrepresented students in the field of cancer research.
Who could benefit from this research
Good fit: Ideal candidates for this research are Black and African American individuals diagnosed with triple negative breast cancer.
Not a fit: Patients who do not identify as Black or African American or those with non-triple negative breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for Black and African American patients with breast cancer.
How similar studies have performed: Previous research has shown promise in targeting specific biomarkers in breast cancer, but this approach is particularly focused on an underserved population, making it a novel initiative.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Connolly, Denise C — Temple Univ of the Commonwealth
- Study coordinator: Connolly, Denise C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.